Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 188,567 shares of the specialty pharmaceutical company’s stock after selling 1,510 shares during the period. Retirement Systems of Alabama’s holdings in Jazz Pharmaceuticals were worth $23,222,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Wedge Capital Management L L P NC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at about $32,497,000. Pacer Advisors Inc. lifted its stake in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after buying an additional 278,465 shares during the period. Cinctive Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the third quarter worth approximately $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in Jazz Pharmaceuticals by 47.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company’s stock valued at $29,945,000 after acquiring an additional 86,768 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the transaction, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. The trade was a 0.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC restated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Piper Sandler reissued an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. TD Cowen dropped their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $120.07 on Friday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The stock’s 50 day moving average price is $122.60 and its 200 day moving average price is $116.32. The firm has a market capitalization of $7.26 billion, a PE ratio of 16.91, a price-to-earnings-growth ratio of 0.90 and a beta of 0.56.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.